Cargando…
Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
Although many strategies have been developed for non-small cell lung cancer (NSCLC), more secondary and further treatments are needed due to drug resistance or tumor recurrence. Apatinib is a novel oral antiangiogenic agent and in this study, we aim to investigate the clinical value of apatinib in h...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6087811/ https://www.ncbi.nlm.nih.gov/pubmed/30108437 http://dx.doi.org/10.1016/j.sjbs.2017.12.011 |